Department of Environmental Health Sciences, Florida International University, Miami, USA.
Biomolecular Sciences Institute, Florida International University, Miami, USA.
Mol Neurodegener. 2024 Mar 19;19(1):26. doi: 10.1186/s13024-024-00708-w.
Dynamin-related protein 1 (Drp1) plays a critical role in mitochondrial dynamics. Partial inhibition of this protein is protective in experimental models of neurological disorders such as Parkinson's disease and Alzheimer's disease. The protective mechanism has been attributed primarily to improved mitochondrial function. However, the observations that Drp1 inhibition reduces protein aggregation in such neurological disorders suggest the involvement of autophagy. To investigate this potential novel protective mechanism of Drp1 inhibition, a model with impaired autophagy without mitochondrial involvement is needed.
We characterized the effects of manganese (Mn), which causes parkinsonian-like symptoms in humans, on autophagy and mitochondria by performing dose-response studies in two cell culture models (stable autophagy HeLa reporter cells and N27 rat immortalized dopamine neuronal cells). Mitochondrial function was assessed using the Seahorse Flux Analyzer. Autophagy flux was monitored by quantifying the number of autophagosomes and autolysosomes, as well as the levels of other autophagy proteins. To strengthen the in vitro data, multiple mouse models (autophagy reporter mice and mutant Drp1 mice and their wild-type littermates) were orally treated with a low chronic Mn regimen that was previously reported to increase α-synuclein aggregation and transmission via exosomes. RNAseq, laser captured microdissection, immunofluorescence, immunoblotting, stereological cell counting, and behavioural studies were used. RESULTS IN VITRO: data demonstrate that at low non-toxic concentrations, Mn impaired autophagy flux but not mitochondrial function and morphology. In the mouse midbrain, RNAseq data further confirmed autophagy pathways were dysregulated but not mitochondrial related genes. Additionally, Mn selectively impaired autophagy in the nigral dopamine neurons but not the nearby nigral GABA neurons. In cells with a partial Drp1-knockdown and Drp1 mice, Mn induced autophagic impairment was significantly prevented. Consistent with these observations, Mn increased the levels of proteinase-K resistant α-synuclein and Drp1-knockdown protected against this pathology.
This study demonstrates that improved autophagy flux is a separate mechanism conferred by Drp1 inhibition independent of its role in mitochondrial fission. Given that impaired autophagy and mitochondrial dysfunction are two prominent features of neurodegenerative diseases, the combined protective mechanisms targeting these two pathways conferred by Drp1 inhibition make this protein an attractive therapeutic target.
动力相关蛋白 1(Drp1)在线粒体动力学中起着关键作用。在帕金森病和阿尔茨海默病等神经退行性疾病的实验模型中,该蛋白的部分抑制具有保护作用。这种保护机制主要归因于改善线粒体功能。然而,观察到 Drp1 抑制减少了这些神经退行性疾病中的蛋白质聚集,这表明自噬的参与。为了研究 Drp1 抑制的这种潜在新的保护机制,需要一种没有线粒体参与的自噬受损的模型。
我们通过在两种细胞培养模型(稳定自噬 HeLa 报告细胞和 N27 大鼠永生化多巴胺神经元细胞)中进行剂量反应研究,来表征锰(Mn)对自噬和线粒体的影响,Mn 会导致人类出现帕金森样症状。使用 Seahorse 通量分析仪评估线粒体功能。通过定量自噬小体和自溶酶体的数量以及其他自噬蛋白的水平来监测自噬流。为了加强体外数据,我们使用了多种小鼠模型(自噬报告小鼠和突变 Drp1 小鼠及其野生型同窝仔鼠)进行了口服低慢性 Mn 治疗,先前的研究表明,这种治疗会通过外泌体增加 α-突触核蛋白的聚集和传递。使用 RNAseq、激光捕获显微解剖、免疫荧光、免疫印迹、立体细胞计数和行为研究进行了分析。
数据表明,在低非毒性浓度下,Mn 会损害自噬流,但不会损害线粒体功能和形态。在小鼠中脑,RNAseq 数据进一步证实了自噬途径失调,但与线粒体相关基因无关。此外,Mn 选择性地损害了黑质多巴胺神经元中的自噬,但对附近的黑质 GABA 神经元没有影响。在部分 Drp1 敲低的细胞和 Drp1 小鼠中,Mn 诱导的自噬损伤明显得到预防。与这些观察结果一致的是,Mn 增加了蛋白水解酶抗性 α-突触核蛋白的水平,而 Drp1 敲低则可以防止这种病理。
本研究表明,改善的自噬流是 Drp1 抑制赋予的独立于其在线粒体分裂中的作用的另一种机制。鉴于自噬和线粒体功能障碍是神经退行性疾病的两个突出特征,Drp1 抑制针对这两个途径的联合保护机制使该蛋白成为一个有吸引力的治疗靶点。